Patents by Inventor Danielle STANISIC

Danielle STANISIC has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230285529
    Abstract: Disclosed are compositions for stimulating a protective or therapeutic immune response to an apicomplexan parasite such as those from the Plasmodium or Babesia genus. More particularly, the compositions comprise a soluble parasite extract. The extract may be free of red blood cell components and/or contained in or associated with a particle such as a liposome. The compositions and methods disclosed herein are particularly useful in the prevention and treatment of parasitic diseases.
    Type: Application
    Filed: November 23, 2020
    Publication date: September 14, 2023
    Applicant: GRIFFITH UNIVERSITY
    Inventors: Michael GOOD, Danielle STANISIC, Ashwini Kumar GIDDAM, Aloysious SSEMEGANDA
  • Patent number: 11406694
    Abstract: Apicomplexan parasites or red blood cells infected with apicomplexan parasites are administered to an animal in combination with a delayed death agent that initially allows parasite replication but subsequently kills the apicomplexan parasites. This allows the elicitation of an immune response by the animal while preventing the parasites producing a serious infection of the animal. The apicomplexan parasites may be malaria or babesia parasites. The delayed death agent may be a tetracycline class antibiotic, a macrolide antibiotic or a lincosamide antibiotic.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: August 9, 2022
    Assignee: Griffith University
    Inventors: Michael Good, Danielle Stanisic, Leanne Low
  • Publication number: 20190224293
    Abstract: Apicomplexan parasites or red blood cells infected with apicomplexan parasites are administered to an animal in combination with a delayed death agent that initially allows parasite replication but subsequently kills the apicomplexan parasites. This allows the elicitation of an immune response by the animal while preventing the parasites producing a serious infection of the animal. The apicomplexan parasites may be malaria or babesia parasites. The delayed death agent may be a tetracycline class antibiotic, a macrolide antibiotic or a lincosamide antibiotic.
    Type: Application
    Filed: October 24, 2016
    Publication date: July 25, 2019
    Applicant: GRIFFITH UNIVERSITY
    Inventors: Michael GOOD, Danielle STANISIC, Leanne LOW